Table 2 Open in new tab Incidence rates...

	Alirocumab vs. placebo	Evolocumab vs. placebo
Efficacy events
All-cause death	354/13 607	0.84	407/11 446	1.02	450/17 931	1.41	431/16 040	1.38
Cardiovascular death	248/13 034	0.59	280/11 217	0.70	254/17 447	0.82	241/15 556	0.79
Myocardial infarction	649/12 873	1.55	748/11 153	1.88	482/16 248	1.53	653/15 099	2.11
Stroke	123/12 300	0.30	155/10 924	0.39	210/15 521	0.68	266/14 865	0.87
Ischaemia-driven coronary revascularization	797/12 300	1.92	862/10 924	2.17	814/15 649	2.64	1034/14 797	3.38
Safety events
Adverse events leading to treatment discontinuation	570/13 565	1.36	424/11 427	1.06	276/17 432	0.89	228/15 532	0.73
Injection site reactions	688/13 414	1.64	302/11 396	0.76	415/17 791	1.31	269/15 984	0.86
Systemic allergic reactions	1056/12 956	2.53	874/11 176	2.20	420/13 769	1.41	393/13 756	1.32
Neurocognitive events	177/12 956	0.42	179/11 176	0.45	225/16 131	0.73	208/15 279	0.68
Ophthalmologic events	207/12 589	0.50	176/10 992	0.44	242/14 514	0.81	244/14 001	0.82
New-onset or worsening of diabetes mellitus	1272/12 232	3.08	1319/10 841	3.33	7/862	4.08	4/429	1.12

Alirocumab vs. placebo

Evolocumab vs. placebo

Alirocumab

Placebo

Evolocumab

Placebo

No. events/ no. patients

Incidence rates (per 100 patient-year)

No. events/ no. patients

Incidence rates (per 100 patient-year)

No. events/ no. patients

Incidence rates (per 100 patient-year)

No. events/ no. patients

Incidence rates (per 100 patient-year)

Efficacy events

All-cause death

354/13 607

0.84

407/11 446

1.02

450/17 931

1.41

431/16 040

1.38

Cardiovascular death

248/13 034

0.59

280/11 217

0.70

254/17 447

0.82

241/15 556

0.79

Myocardial infarction

649/12 873

1.55

748/11 153

1.88

482/16 248

1.53

653/15 099

2.11

Stroke

123/12 300

0.30

155/10 924

0.39

210/15 521

0.68

266/14 865

0.87

Ischaemia-driven coronary revascularization

797/12 300

1.92

862/10 924

2.17

814/15 649

2.64

1034/14 797

3.38

Safety events

Adverse events leading to treatment discontinuation

570/13 565

1.36

424/11 427

1.06

276/17 432

0.89

228/15 532

0.73

Injection site reactions

688/13 414

1.64

302/11 396

0.76

415/17 791

1.31

269/15 984

0.86

Systemic allergic reactions

1056/12 956

2.53

874/11 176

2.20

420/13 769

1.41

393/13 756

1.32

Neurocognitive events

177/12 956

0.42

179/11 176

0.45

225/16 131

0.73

208/15 279

0.68

Ophthalmologic events

207/12 589

0.50

176/10 992

0.44

242/14 514

0.81

244/14 001

0.82

New-onset or worsening of diabetes mellitus

1272/12 232

3.08

1319/10 841

3.33

7/862

4.08

4/429

1.12

	Alirocumab vs. placebo	Evolocumab vs. placebo
Efficacy events
All-cause death	354/13 607	0.84	407/11 446	1.02	450/17 931	1.41	431/16 040	1.38
Cardiovascular death	248/13 034	0.59	280/11 217	0.70	254/17 447	0.82	241/15 556	0.79
Myocardial infarction	649/12 873	1.55	748/11 153	1.88	482/16 248	1.53	653/15 099	2.11
Stroke	123/12 300	0.30	155/10 924	0.39	210/15 521	0.68	266/14 865	0.87
Ischaemia-driven coronary revascularization	797/12 300	1.92	862/10 924	2.17	814/15 649	2.64	1034/14 797	3.38
Safety events
Adverse events leading to treatment discontinuation	570/13 565	1.36	424/11 427	1.06	276/17 432	0.89	228/15 532	0.73
Injection site reactions	688/13 414	1.64	302/11 396	0.76	415/17 791	1.31	269/15 984	0.86
Systemic allergic reactions	1056/12 956	2.53	874/11 176	2.20	420/13 769	1.41	393/13 756	1.32
Neurocognitive events	177/12 956	0.42	179/11 176	0.45	225/16 131	0.73	208/15 279	0.68
Ophthalmologic events	207/12 589	0.50	176/10 992	0.44	242/14 514	0.81	244/14 001	0.82
New-onset or worsening of diabetes mellitus	1272/12 232	3.08	1319/10 841	3.33	7/862	4.08	4/429	1.12

Table 2

Open in new tab

Incidence rates of adverse events

	Alirocumab vs. placebo				Evolocumab vs. placebo
	Alirocumab		Placebo		Evolocumab		Placebo
	No. events/ no. patients	Incidence rates (per 100 patient-year)	No. events/ no. patients	Incidence rates (per 100 patient-year)	No. events/ no. patients	Incidence rates (per 100 patient-year)	No. events/ no. patients	Incidence rates (per 100 patient-year)
Efficacy events
All-cause death	354/13 607	0.84	407/11 446	1.02	450/17 931	1.41	431/16 040	1.38
Cardiovascular death	248/13 034	0.59	280/11 217	0.70	254/17 447	0.82	241/15 556	0.79
Myocardial infarction	649/12 873	1.55	748/11 153	1.88	482/16 248	1.53	653/15 099	2.11
Stroke	123/12 300	0.30	155/10 924	0.39	210/15 521	0.68	266/14 865	0.87
Ischaemia-driven coronary revascularization	797/12 300	1.92	862/10 924	2.17	814/15 649	2.64	1034/14 797	3.38
Safety events
Adverse events leading to treatment discontinuation	570/13 565	1.36	424/11 427	1.06	276/17 432	0.89	228/15 532	0.73
Injection site reactions	688/13 414	1.64	302/11 396	0.76	415/17 791	1.31	269/15 984	0.86
Systemic allergic reactions	1056/12 956	2.53	874/11 176	2.20	420/13 769	1.41	393/13 756	1.32
Neurocognitive events	177/12 956	0.42	179/11 176	0.45	225/16 131	0.73	208/15 279	0.68
Ophthalmologic events	207/12 589	0.50	176/10 992	0.44	242/14 514	0.81	244/14 001	0.82
New-onset or worsening of diabetes mellitus	1272/12 232	3.08	1319/10 841	3.33	7/862	4.08	4/429	1.12

	Alirocumab vs. placebo				Evolocumab vs. placebo
	Alirocumab		Placebo		Evolocumab		Placebo
	No. events/ no. patients	Incidence rates (per 100 patient-year)	No. events/ no. patients	Incidence rates (per 100 patient-year)	No. events/ no. patients	Incidence rates (per 100 patient-year)	No. events/ no. patients	Incidence rates (per 100 patient-year)
Efficacy events
All-cause death	354/13 607	0.84	407/11 446	1.02	450/17 931	1.41	431/16 040	1.38
Cardiovascular death	248/13 034	0.59	280/11 217	0.70	254/17 447	0.82	241/15 556	0.79
Myocardial infarction	649/12 873	1.55	748/11 153	1.88	482/16 248	1.53	653/15 099	2.11
Stroke	123/12 300	0.30	155/10 924	0.39	210/15 521	0.68	266/14 865	0.87
Ischaemia-driven coronary revascularization	797/12 300	1.92	862/10 924	2.17	814/15 649	2.64	1034/14 797	3.38
Safety events
Adverse events leading to treatment discontinuation	570/13 565	1.36	424/11 427	1.06	276/17 432	0.89	228/15 532	0.73
Injection site reactions	688/13 414	1.64	302/11 396	0.76	415/17 791	1.31	269/15 984	0.86
Systemic allergic reactions	1056/12 956	2.53	874/11 176	2.20	420/13 769	1.41	393/13 756	1.32
Neurocognitive events	177/12 956	0.42	179/11 176	0.45	225/16 131	0.73	208/15 279	0.68
Ophthalmologic events	207/12 589	0.50	176/10 992	0.44	242/14 514	0.81	244/14 001	0.82
New-onset or worsening of diabetes mellitus	1272/12 232	3.08	1319/10 841	3.33	7/862	4.08	4/429	1.12

no., number of.

This Feature Is Available To Subscribers Only